Monthly Archives: February 2022

This survey assessed biosimilar beliefs among patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis (PsO) and/or psoriatic arthritis (PsA). We report here on patients with IBD. Continue reading →

Diagnosis of ulcerative colitis (UC), a subgroup of inflammatory bowel disease (IBD), is frequently overlooked among the Hispanic population. Although previously thought to impact predominantly white populations, epidemiological studies have shown an i… Continue reading →

We have previously published the results of an infliximab (IFX) population PK model in children and young adults with Crohn’s disease (CD). We found that prediction accuracy was improved with less unexplained variability when the five covariates of dru… Continue reading →

Brain fog has been extensively studied in patients with inflammatory bowel disease (IBD). Probiotics have been shown to increase the incidence of brain fog in patients independently. There is a high prevalence of probiotic consumption in patients with … Continue reading →

Inflammatory bowel disease (IBD), consisting of both Crohn’s Disease (CD) and ulcerative colitis (UC), affects nearly 80,000 children in the United States. African American patients have more perirectal phenotype which might indicate more severe diseas… Continue reading →

Microbiome-driven drug discovery holds great promise for therapeutic development. However, identification of disease-associated microbiome-host interactions are challenging, owing largely to the complexity of a diverse community and the myriad of direc… Continue reading →

Disease-related stigmatization is present in IBD, with a substantial proportion of patients reporting that they perceive discriminatory attitudes or behaviors from others because of their IBD status. These perceptions are associated with poor outcomes…. Continue reading →

IBD patients can have reduced gut commensal abundance, relative expansion of pro-inflammatory taxa, and reduced microbial diversity and short-chain fatty acid production. FMT leads to clinical remission in some UC patients, but is a complex, nonscalabl… Continue reading →

Inflammatory bowel disease (IBD) is likely to have an impact on sexual function because of its symptoms like diarrhea, fatigue and abdominal pain. The impact of the disease on sexuality and intimacy is one of the main concerns of IBD patients but there… Continue reading →

Anti-TNF-alpha therapy is an established treatment modality for inflammatory bowel disease (IBD). Yet up to 30% of patients do not respond to anti-TNF-alpha therapy (primary non-responders), and almost 50% of responders lose clinical efficacy over time… Continue reading →